Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®

NCT07495930 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Health Adult Subjects

Interventions

DRUG: HLX319
DRUG: EU-Phesgo

Sponsor

Shanghai Henlius Biotech